Cara Therap Drug Patent Portfolio

Cara Therap owns 1 orange book drug protected by 12 US patents Given below is the list of Cara Therap's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10017536 Synthetic peptide amides and dimers thereof 12 Nov, 2027
Active
US10138270 Synthetic peptide amides 12 Nov, 2027
Active
US10793596 Synthetic peptide amides 12 Nov, 2027
Active
US7402564 Synthetic peptide amides 12 Nov, 2027
Active
US7713937 Synthetic peptide amides and dimeric forms thereof 12 Nov, 2027
Active
US7727963 Synthetic peptide amides 12 Nov, 2027
Active
US8217007 Synthetic peptide amides 12 Nov, 2027
Active
US8236766 Uses of synthetic peptide amides 12 Nov, 2027
Active
US8486894 Synthetic peptide amides and dimeric forms thereof 12 Nov, 2027
Active
US8536131 Synthetic peptide amides and dimers thereof 12 Nov, 2027
Active
US9334305 Synthetic peptide amides and dimers thereof 12 Nov, 2027
Active
US9359399 Synthetic peptide amides 12 Nov, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Cara Therap.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US7402564
transaction for FDA Determination of Regulatory Review Period 28 Nov, 2023 US7402564
Payment of Maintenance Fee, 4th Yr, Small Entity 06 Oct, 2023 US10793596
Payment of Maintenance Fee, 12th Yr, Small Entity 07 Aug, 2023 US8236766
Payment of Maintenance Fee, 12th Yr, Small Entity 12 Jul, 2023 US8217007
Payment of Maintenance Fee, 8th Yr, Small Entity 12 Jun, 2023 US9359399
Payment of Maintenance Fee, 8th Yr, Small Entity 11 May, 2023 US9334305
Second letter to regulating agency to determine regulatory review period 26 Jan, 2023 US7402564
Letter from FDA or Dept of Agriculture re PTE application 28 Sep, 2022 US7402564
Payment of Maintenance Fee, 4th Yr, Small Entity 26 May, 2022 US10138270
Patent Term Extension (156) Dismissed 12 Jan, 2022 US7402564
Payment of Maintenance Fee, 4th Yr, Small Entity 07 Jan, 2022 US10017536
Payment of Maintenance Fee, 12th Yr, Small Entity 19 Nov, 2021 US7727963
Payment of Maintenance Fee, 12th Yr, Small Entity 10 Nov, 2021 US7713937
Payment of Maintenance Fee, 8th Yr, Small Entity 05 Mar, 2021 US8536131


Cara Therap's Family Patents

Cara Therap drugs have patent protection in a total of 24 countries. It's US patent count contributes only to 45.7% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Cara Therap Drug List

Given below is the complete list of Cara Therap's drugs and the patents protecting them.


1. Korsuva

Korsuva is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10017536 Synthetic peptide amides and dimers thereof 12 Nov, 2027
(2 years from now)
Active
US10138270 Synthetic peptide amides 12 Nov, 2027
(2 years from now)
Active
US10793596 Synthetic peptide amides 12 Nov, 2027
(2 years from now)
Active
US7402564 Synthetic peptide amides 12 Nov, 2027
(2 years from now)
Active
US7713937 Synthetic peptide amides and dimeric forms thereof 12 Nov, 2027
(2 years from now)
Active
US7727963 Synthetic peptide amides 12 Nov, 2027
(2 years from now)
Active
US8217007 Synthetic peptide amides 12 Nov, 2027
(2 years from now)
Active
US8236766 Uses of synthetic peptide amides 12 Nov, 2027
(2 years from now)
Active
US8486894 Synthetic peptide amides and dimeric forms thereof 12 Nov, 2027
(2 years from now)
Active
US8536131 Synthetic peptide amides and dimers thereof 12 Nov, 2027
(2 years from now)
Active
US9334305 Synthetic peptide amides and dimers thereof 12 Nov, 2027
(2 years from now)
Active
US9359399 Synthetic peptide amides 12 Nov, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Korsuva's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List